HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

Shares of Omeros touched a 52-week high, a day after the company said it could resubmit its biologics license application for narsoplimab to the Food and Drug Administration. In Thursday afternoon ...

today announced the initiation of its Biologics License Application (BLA) submission to the Drug Regulatory Authority of ...

Reports Q3 revenue $0 vs. $0 last year. “With the acceptance of our Biologics License Application resubmission for pz-cel, we are ramping up our commercial readiness efforts, especially with respect ...

today announced the initiation of its Biologics License Application (BLA) submission to the Drug Regulatory Authority of Pakistan (DRAP) for the conditional approval of its PIKA rabies vaccine for ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

The Food and Drug Administration (FDA) has accepted for review the resubmitted Biologics License Application (BLA) for prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis ...

The FDA has previously granted orphan drug designation to VCN-01 in this indication. If a Biologics License Application for VCN-01 for the treatment of retinoblastoma is ultimately approved by the FDA ...